Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Eli Lilly and Company 10-Q filed Aug 5, 2026
What changed
Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 30, 2026: 10 added · 3 removed · 21 modified; 5 with only figures updated
-
Modified · Financial Results
Revenue increased for the three and six months ended
March 31June 30, 2026, driven primarily by increased volume, partially offset by lower realized prices. The increased volume and the lower realized prices during the three and six months endedMarch 31June 30, 2026 were primarily driven by Mounjaro and Zepbound.